Literature DB >> 24957413

Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML.

Felix S Lichtenegger1, Robin Lorenz2, Katharina Gellhaus3, Wolfgang Hiddemann4, Barbara Beck2, Marion Subklewe5.   

Abstract

Cyclic cytotoxic maintenance therapy can be applied to patients with AML in post-remission. We studied the immune status of AML patients in complete remission and the effect of maintenance therapy on different immune cell populations. Patients in complete remission had reduced NK, TH and Treg counts and a reduced NK activation capacity. In the course of cytotoxic maintenance therapy, NK counts further declined, while TH and Treg cells increased, with lower proliferative potential of TH cells. We conclude that immunotherapeutic approaches in post-remission have to consider reduced NK cell function and further impairment of cellular immune responses during cytotoxic therapy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Cytotoxic therapy; Immunomonitoring; Maintenance therapy; NK cell; T regulatory cell

Mesh:

Year:  2014        PMID: 24957413     DOI: 10.1016/j.leukres.2014.05.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  18 in total

Review 1.  Programmed death-1 checkpoint blockade in acute myeloid leukemia.

Authors:  Alison Sehgal; Theresa L Whiteside; Michael Boyiadzis
Journal:  Expert Opin Biol Ther       Date:  2015-06-03       Impact factor: 4.388

Review 2.  New approaches for the immunotherapy of acute myeloid leukemia.

Authors:  Terrence L Geiger; Jeffrey E Rubnitz
Journal:  Discov Med       Date:  2015-04       Impact factor: 2.970

Review 3.  Alterations of T-cell-mediated immunity in acute myeloid leukemia.

Authors:  Zhuoyan Li; Mary Philip; P Brent Ferrell
Journal:  Oncogene       Date:  2020-03-03       Impact factor: 9.867

4.  Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.

Authors:  David A Knorr; Aaron D Goldberg; Eytan M Stein; Martin S Tallman
Journal:  Leuk Lymphoma       Date:  2019-07-23

5.  Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.

Authors:  Fabiana Perna; Manuel R Espinoza-Gutarra; Giuseppe Bombaci; Sherif S Farag; Jennifer E Schwartz
Journal:  Cancer Treat Res       Date:  2022

Review 6.  Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Authors:  Georgios Petros Barakos; Eleftheria Hatzimichael
Journal:  Diseases       Date:  2022-06-10

7.  Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells.

Authors:  Grace Lee; Sheela Karunanithi; Bruce Posner; Hanspeter Niederstrasser; Hong Cheng; Yuriy Federov; Shivaprasad Manjappa; Karam Musaitif; Huaiyu Wang; Zachary Jackson; David Wald
Journal:  Cancer Immunol Immunother       Date:  2021-11-23       Impact factor: 6.630

8.  T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.

Authors:  Frauke M Schnorfeil; Felix S Lichtenegger; Katharina Emmerig; Miriam Schlueter; Julia S Neitz; Rika Draenert; Wolfgang Hiddemann; Marion Subklewe
Journal:  J Hematol Oncol       Date:  2015-07-30       Impact factor: 17.388

9.  Repression of GSK3 restores NK cell cytotoxicity in AML patients.

Authors:  Reshmi Parameswaran; Parameswaran Ramakrishnan; Stephen A Moreton; Zhiqiang Xia; Yongchun Hou; Dean A Lee; Kalpana Gupta; Marcos deLima; Rose C Beck; David N Wald
Journal:  Nat Commun       Date:  2016-04-04       Impact factor: 14.919

10.  Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Authors:  Anna Martner; Anna Rydström; Rebecca E Riise; Johan Aurelius; Harald Anderson; Mats Brune; Robin Foà; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.